Glucose metabolism and hyperglycemia

American Journal of Clinical Nutrition

Volumn 87, Issue 1, 2008, Pages

  Giugliano, Dario ^a,c   Ceriello, Antonio ^b   Esposito, Katherine ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c NONE   (Italy)

Author keywords

Cardiovascular disease risk; Fasting hyperglycemia; Glycated hemoglobin; Lifestyle; Postprandial hyperglycemia; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; VASCULAR DISEASE;

EID: 38149010468     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/87.1.217s     Document Type: Conference Paper

References (74)

1. Garber AJ, Cryer PE, Santiago JV, et al. The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest 1976;58:7-15.
2. Radziuk J, McDonald TJ, Rubenstein D, et al. Initial splanchnic extraction of ingested glucose in normal men. Metabolism 1978;27:657-69.
3. Rizza RA, Mandarino L, Gerich JE. Dose-response characteristics for the effects of insulin on production and utilization of glucose in man. Am J Physiol 1981;240:630-9.
4. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969;48:810-22.
5. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 2001;17:983-9.
6. Wolever TMS, Chiasson JL, Csima A, et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998;21:336-40.
7. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
8. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
9. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.
10. Gerstein HC, Capes SE. Dysglycemia: a key cardiovascular risk factor. Semin Vasc Med 2002;2:165-74.
11. Steinbrook R. Facing the diabetes epidemic-mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med 2006;354:545-8.
12. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-90.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
15. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(suppl):S4-36.
16. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42.
17. American College of Endocrinology. Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002;8(suppl):5-11.
18. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
19. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobinA1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004;141:413-20.
20. Gerstein HC. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann Intern Med 2004;141:475-6.
21. Pecoraro RE, Chen MS, Porte D Jr. Glycosylated hemoglobin and fasting plasma glucose in the assessment of outpatient glycemic control in NIDDM. Diabetes Care 1982;5:592-9.
22. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-8.
23. Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA1c interrelationship in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023-9.
24. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988;37:1020-4.
25. Riddle MC. Evening insulin strategy. Diabetes Care 1990;13:676-86.
26. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003;26:881-5.
27. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CDA, Nijpels GBLM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31.
28. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987;36:689-92.
29. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycaemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163-9.
30. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.
31. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged non diabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-7.
32. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.
33. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813-9.
34. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
35. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94.
36. Zeymer U, Schwarzmaier-D'assie A, Petzinna D, Chiasson JL. STOP-NIDDM Trial Research Group. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. Eur J Cardiovasc Prev Rehabil 2004;11:412-5.
37. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-6.
38. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus. Circulation 2004;110:214-9.
39. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
40. Brownlee M. The pathophysiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25.
41. Ceriello A, Quagliano L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002;25:1439-43.
42. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424-37.
43. Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003;289:1675-80.
44. Pennathur S, Wagner JD, Leeuwenburgh C, et al. A hydroxyl radical like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001;107:853-60.
45. Ceriello A, Quagliaro L, D'Amico M, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 2002;51:1076-82.
46. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001;108:635-6 (letter).
47. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Effects of short- and long-term simvastatin treatment. Circulation 2002;106:1211-8.
48. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002;25:737-41.
49. Trovati M, Burzacca S, Mularovi E, et al. Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycemic agents: importance of blood glucose monitoring. Diabetologia 1991;34:662-7.
50. Monnier L, Colette C, Lapinski H. Global assessment for quality and safety of control in type 2 diabetic patients. Eur J Clin Invest 2004;34:37-42.
51. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7.
52. Esposito K, Nappo F, Martella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72.
53. Giugliano D, Martella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997;95:1783-90.
54. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006;49:846-54.
55. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001;24:775-8.
56. Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005;48:1919-24.
57. Ceriello A, Piconi L, Quagliaro L, et al. Effects of pramlintide on post-prandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005;28:632-7.
58. Manzella D, Grella R, Abbatecola AM, Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005;28:366-71.
59. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004;21:171-5.
60. Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in type 2 diabetic patients. Diabet Med 2004;21:983-6.
61. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006;91:837-42.
62. Scognamiglio R, Negut C, de Kreutzenberg SV, Tiengo A, Avogaro A. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 2006;29:95-100.
63. Rudofsky G Jr, Reismann P, Schiekofer S, et al. Reduction of postprandial hyperglycaemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res 2004;36:630-8.
64. Bae JH, Bassenge E, Kim KB, et al. Postprandial hypertriglyceridaemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 2001;155:517-23.
65. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004;53:701-10.
66. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006;116:1071-80.
67. Esposito K, Giugliano D. Diet and inflammation: a link to metabolic and cardiovascular diseases. Eur Heart J 2006;27:15-20.
68. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
69. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
70. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
71. Giugliano D, Esposito K. Optimal treatment for the metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:e30.
72. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292:1440-6.
73. Orchard TJ, Tempros M, Goldberg R, et al. Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-9.
74. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a dietary approaches to stop hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005;28:2823-31.